LENZ submits NDA for LNZ100 (aceclidine) to FDA for presbyopia treatment

LENZ Therapeutics, Inc.

NDA supported by Phase 3 CLARITY study: met all primary and secondary near vision endpoints.
LNZ100 is an aceclidine-based eye drop targeting presbyopia, affecting ~1.8B people globally.
No serious treatment-related adverse events observed over 30,000 study days.
FDA has 60-day filing review period to determine NDA completeness for acceptance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.